CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Burden of Cardiovascular Diseases in China, 1990-2016: Findings From the 2016 Global Burden of Disease Study Coronary calcium as a predictor of coronary events in four racial or ethnic groups The Burden of Cardiovascular Diseases Among US States, 1990-2016 ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)

GuidelineVolume 73, Issue 24, June 2019

JOURNAL:J Am Coll Cardiol. Article Link

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

SM Grundy, NJ Stone, AL Bailey et al. Keywords: ACC/AHA Clinical Practice Guidelines; biomarkers; coronary artery calcium score; pharmacological; cardiovascular disease; cholesterol; LDL-cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention; ezetimibe; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors

FULL TEXT PDF